Cyclooxygenase (COX)-2-specific inhibitors were developed to circumvent the gastrointestinal @entity137 of non-specific non-steroidal anti-inflammatory drugs while maintaining efficacy. However, the higher acquisition cost of @entity2247 -specific inhibitors has resulted in the implementation of a programme for cost containment in the Ontario public drug program. This programme consists of limited use (LU) criteria that need to be met for drug reimbursement of @entity1 with @entity571 ( @entity571 ) or @entity309 ( @entity309 ). Determining the proportion of @entity1 eligible for reimbursement for @entity12698 according to the LU criteria (based on prior treatment failure and the presence or history of serious ulcer-related @entity344 ) can provide an indication of the extent of adherence to suggested guidelines. Using a @entity1 -based survey and an analysis of the Ontario Drug Benefit Program database, the proportion of @entity1 prescribed @entity12698 who met rigorous or pragmatic definitions of the LU criteria was determined. The extent of coprescription of gastroprotective agents among @entity1 taking @entity12698 was also determined. Using the pragmatic definition, the majority of @entity1 in the @entity1 -based survey (53% for @entity571 and 81% for @entity309 ) met the LU criteria. Similarly, in the database analysis, the majority of @entity1 (76% for @entity571 and 78% for @entity309 ) met the LU criteria. These data suggest that physician prescribing of @entity12698 is consistent with the LU criteria. Concomitant prescription of gastroprotective agents in @entity1 taking @entity12698 was approximately 40%. It is recommended that further investigations be performed to determine the long-term impact of LU criteria on clinical and economic outcomes, since these criteria may also serve to restrict use in @entity1 who may benefit from taking @entity2247 -specific inhibitors.

Drug utilization review of XXXX in Ontario.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity12698 :: ('MESH:C105934', 'Chemical') :: ['celecoxib'] @entity571 :: ('MESH:D010003', 'Disease') :: ['osteoarthritis', 'OA'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal complications'] @entity2247 :: ('4513', 'Gene') :: ['COX-2'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity12698 :: (MESH:C105934,Chemical) :: ['celecoxib']
